COMPLIANCE CHAMBERS FOR ARTIFICIAL HEART IMPLANTS

人工心脏植入物的顺应室

• 批准号: 2716914
• 负责人: JUMARASWAMY JAYARAJ
• 金额: $ 9.81万
• 依托单位: FOSTER-MILLER, INC.
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-09-15 至 1999-03-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2716914
• 关键词: auxiliary heart prosthesis; bioengineering /biomedical engineering; biomaterial compatibility; biomaterial development /preparation; biomaterial interface interaction; biomaterials; biomedical equipment development; circulatory assist; clinical biomedical equipment; diffusion; heart prosthesis; laboratory mouse; laboratory rabbit; liquid crystal; polymers; tensile strength

DESCRIPTION (Adapted from applicant's abstract): The intrathoracic compliance chamber (ICC) is the most successful solution to the variable volume problem of a totally implanted pulsatile artificial heart. However, existing designs are compromised by the rate at which gas permeates through he chamber walls, given that all polymeric membranes are subject to some degree of gas permeation. Given this limitation, percutaneous gas refills would be required at frequent intervals, measured in weeks. It is the applicants' hypothesis that this limitation can be remedied by the use of liquid crystal polymers (LCPs), a material class of remarkable mechanical properties, high chemical inertness, and extremely low permeability (essentially equivalent to glass). The applicants proposes to develop the materials and processes for the fabrication of vastly improved ICCs. The applicants plan to demonstrate that LCPs have the biocompatibility, low permeability, high fatigue resistance, and sufficient manufacturability to be ideal candidates for ventricular assist system and artificial heart compliance chambers. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

描述（改编自申请人的摘要）：intrathoracic 合规室（ICC）是变量最成功的解决方案 完全植入的脉动人造心脏的体积问题。 但是，现有设计被气体的速率损害 鉴于所有聚合物膜都是 受到一定程度的气体渗透。 考虑到这个限制， 经常需要频繁的间隔，测量经皮气体补充 在几周内。 申请人的假设是，这种限制可以是 通过使用液晶聚合物（LCP）来纠正，这是一种材料类别的类别 显着的机械性能，高化学惰性和极度 低渗透性（基本上等于玻璃）。 申请人 建议开发制造的材料和过程 大大改善了ICC。 申请人计划证明LCP具有生物相容性， 低渗透性，高疲劳性和足够 成为心室辅助系统的理想候选者的制造性和 人造心脏合规室。 拟议的商业应用程序：不可用